167 related articles for article (PubMed ID: 38318097)
1. Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study.
Bai H; Wang WH; Zhou FF; Yang D; Li RJ
Cancer Manag Res; 2024; 16():73-86. PubMed ID: 38318097
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
Dou XJ; Ma RY; Ren DW; Liu Q; Yan P
Lung Cancer (Auckl); 2024; 15():29-40. PubMed ID: 38560413
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma.
Sun X; Xu J; Xie L; Guo W
Int J Gen Med; 2022; 15():7581-7591. PubMed ID: 36196372
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study.
Li S; Zheng H; Ge Q; Xia S; Zhang K; Wang C; Wang F
J Cancer Prev; 2023 Sep; 28(3):106-114. PubMed ID: 37830117
[TBL] [Abstract][Full Text] [Related]
5. Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer.
Hao YY; Qiao YP; Cheng JD
Int J Gen Med; 2021; 14():10483-10493. PubMed ID: 35002304
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study.
Li XY; Rao Y; Sun B; Mao XM
Int J Gen Med; 2022; 15():3977-3989. PubMed ID: 35440872
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study.
Jia M; Jia JK; Xu J; Xue HZ
Cancer Manag Res; 2022; 14():2625-2638. PubMed ID: 36081824
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
Zhang S; Wang X; Gu H; Liu JQ
Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.
Hu WX; Peng JC; Wang Y; Jin H; Geng N
Int J Gen Med; 2022; 15():4453-4464. PubMed ID: 35509604
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Jiang HT; Li W; Zhang B; Gong Q; Qie HL
Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
Li LH; Chen WC; Wu G
Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
Li Y; Sun Z; Sun W; Wang H; Zu J
Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
Chen XQ; Zhao YX; Zhang CL; Wang XT; Zhang X; Chen X; Yuan CW; Zhao Q; Chen XJ
Drug Des Devel Ther; 2022; 16():1483-1493. PubMed ID: 35607597
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions.
Song PF; Xu N; Li Q
Cancer Manag Res; 2020; 12():11133-11143. PubMed ID: 33173346
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
Qin BD; Jiao XD; Wang Z; Liu K; Wu Y; Ling Y; Chen SQ; Zhong X; Duan XP; Qin WX; Xue L; Guo ZH; Zang YS
Int J Cancer; 2023 Aug; 153(4):815-825. PubMed ID: 37155342
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]